Alexis Turgeon

Alexis Turgeon is a Professor and Director of Research in the Department of Anesthesiology and Critical Care Medicine at Université Laval. He practices Critical Care Medicine and Anesthesiology at the CHU de Québec - Université Laval (Hôpital de l’Enfant-Jésus) in Québec City. Alexis Turgeon first graduated from Université Laval medical school in 1999 and, following residency training in Anesthesiology, he completed a master’s degree in Clinical Epidemiology. He pursued training in Critical Care Medicine at the University of Ottawa along with a research fellowship at the Clinical Epidemiology Unit of the Ottawa Hospital Research Institute. He is a scientist in the Population Health and Optimal Practices Unit (Trauma - Emergency - Critical Care Medicine) of the CHU de Québec-Université Laval Research Center.
 

Dr Turgeon is the Director of Cochrane Canada Francophone, the co-Chair of the Canadian Traumatic brain injury Research Consortium (CTRC) and the chairholder of the Canada Research Chair in Critical Care Neurology and Trauma. With colleagues, he leads a comprehensive research program in neurocritically ill patients including an international multicenter trial (HEMOTION Trial), the NeurO2 study and BRAINapt, a platform trial in critically ill patients with TBI. His program is funded by the Canadian Institutes of Health Research (CIHR) and the Canada Foundation for Innovation.  During the pandemic and following the call by the CIHR for COVID-19 research, he oriented part of his research and obtained CIHR funding to evaluate the use of convalescent plasma within the REMAP-CAP international adaptive platform trial, as well as therapeutic anticoagulants in the same platform with other Canadian colleagues.

Dr Turgeon is the chairholder of the Canada Research Chair in Critical Care Neurology and Trauma.